Metera Pharmaceuticals

Metera Pharmaceuticals is a private biotechnology company focused on therapies for serious respiratory diseases. Its lead disclosed program, MPX-111, is an inhaled small-molecule remodeling kinase inhibitor being developed as a potential disease-modifying treatment for idiopathic pulmonary fibrosis. Publicly available sources characterize the company as preclinical-stage and indicate a lean operating footprint in Massachusetts. The company appears to have pursued non-dilutive funding, including U.S. government support, to advance its lead program. Overall, Metera is a small, respiratory-focused biotech centered on a single disclosed preclinical fibrosis asset.